Metabolic osteoarthritis · hand joints

Metabolic Osteoarthritis: Screening the Hand and Younger Joint

Metabolic osteoarthritis screening belongs in two presentations: osteoarthritis in the finger joints, which carry almost no load, and osteoarthritis that starts unexpectedly young. In both, a glycemic, insulin and lipid panel is the right first test.

Load explains the knee. It does not explain the interphalangeal joint, and it does not explain a fifty-year-old with four affected sites. Those two presentations are the screening trigger.

Metabolic screening in osteoarthritis is usually skipped for a reason that sounds like physiology: the joint hurts because it carries weight. That reasoning holds at the knee and collapses in the hand. The distal and proximal interphalangeal joints carry essentially nothing, and they are where the systemic signal separates most cleanly from the load signal. So does age at onset. Those two presentations, the inflamed hand and the unexpectedly young joint, are where a referral for a brace and an analgesic is answering the wrong question, and a glycemic, insulin and lipid panel is the right first one.

What the adjusted data support, and what they do not

Be precise, because this literature is overstated in both directions. Diabetes and osteoarthritis travel together: a meta-analysis of 49 studies put the odds of osteoarthritis in diabetes at 1.46, with an average osteoarthritis prevalence of 29.5% among 5788 patients with diabetes. Of the 12 included studies that adjusted for body mass index, 7 kept diabetes as an independent risk factor and 5 did not. That split is the honest state of the field.

Adiposity carries the strongest causal signal. In a Swedish general-population cohort of 10,633 adults with no osteoarthritis diagnosis and no joint pain at baseline, metabolic syndrome carried a hazard of 1.17 for incident osteoarthritis in any joint. Elevated waist circumference alone carried 1.42, and metabolic syndrome without an elevated waist carried 1.02, which is nothing. Across 271,019 participants from the UK Biobank and the National Health and Nutrition Examination Survey, with Mendelian randomization alongside, metabolic syndrome was not an independent risk factor once body mass index was accounted for, risk began climbing around a body mass index of 27, and waist circumference was the component that mattered, the argument behind screening visceral adiposity beyond BMI.

The loading model is not wrong; it is incomplete, and the genetics say so. A cross-trait analysis found a genetic correlation between metabolic syndrome and osteoarthritis of 0.393, with Mendelian randomization supporting liability to metabolic syndrome raising osteoarthritis risk and no reverse effect. Staging the whole cardiometabolic picture sharpens it further. Among 256,364 UK Biobank participants without osteoarthritis at baseline, the most advanced cardiovascular-kidney-metabolic stage carried hazards of 1.76 for hip and 2.67 for knee osteoarthritis against stage 0, and the associations were stronger in younger participants.

The hand is the phenotype that survives adjustment

This is the finding that should change a referral note. In 952 women aged 45 to 65 from the Chingford cohort, metabolic syndrome was associated with painful knee osteoarthritis until body mass index entered the model, at which point it vanished. The association with painful interphalangeal osteoarthritis survived adjustment for both age and body mass index, and four of the five syndrome components tracked with it. Weight itself is associated with hand osteoarthritis: a systematic review of 25 studies graded the evidence moderate with an approximate risk ratio of 1.9, which load cannot explain in a joint that bears no body weight; the same logic already makes carpal tunnel a diabetes screening trigger. In a dedicated hand osteoarthritis cohort, metabolic syndrome went with more pain independent of structural damage and of anxiety and depression scores.

Two biological drivers account for that. Adipose tissue is an endocrine organ, and the metaflammation it generates, adipokines and cytokines, reaches cartilage in the finger as readily as cartilage in the knee. Hyperglycemia acts on the tissue itself, through glycation and oxidative stress in a matrix that turns over slowly. The third driver is structural: osteoarthritis is coded, referred and treated as a mechanical diagnosis, so the patient goes to physical therapy or an injector and nobody is assigned the terrain. Dr. Padda admits to years of closing visits by telling patients with a borderline A1c that the number could wait. A hand radiograph in that patient is a second chance to stop saying it. Periodontal inflammation is another tissue signal that runs ahead of a metabolic diagnosis, set out in sugar, gum inflammation and what to measure.

What a finding changes in management

Three things, and none is a new drug.

First, the weight conversation becomes a measured intervention with a comparator rather than a handout. In a 68-week randomized trial of 407 adults with obesity and moderate knee osteoarthritis, once-weekly semaglutide produced a mean weight change of -13.7% against -3.2% on placebo, with pain scores falling -41.7 points against -27.5. That is what treating adiposity as the driver can do.

Second, body composition changes the target. A meta-analysis of 12 studies found low muscle mass index associated with knee osteoarthritis at 1.36 and sarcopenic obesity at 1.78, on low-quality evidence. A patient who loses weight and keeps losing muscle has not improved, and only measured body composition shows it. Loading and protein intake are treatment, each with its physiological rationale documented.

Third, fall risk enters the plan. Across 17 studies and 862,849 participants, symptomatic knee osteoarthritis carried 1.55 times the odds of recurrent falls. In an older patient with knee pain, sarcopenic obesity and unsteadiness, the joint diagnosis and the fall risk are one problem.

None of this argues against the injection. A joint injection is the bridge: it controls pain now so the patient can load the joint, sleep and do the metabolic work. The failure mode is a bridge with nothing on the other side, and the metabolic panel is how the other side gets built. Patients who ache in several joints at once often carry the visceral pattern described in the MRI evidence linking belly fat to chronic pain.

Who to test

• Any patient with hand osteoarthritis, particularly interphalangeal involvement with pain out of proportion to radiographic grade.
• Osteoarthritis at an age or in a joint distribution that load does not explain, including multi-joint disease before the sixth decade.
• Patients whose waist circumference is above target regardless of body mass index category.
• Patients with diabetes or an A1c in the prediabetic band being referred for injection, physical therapy or arthroplasty evaluation.
• Older patients with knee or hip osteoarthritis who report unsteadiness, a near-fall or a fall.
• Patients told to lose weight at several visits in a row without any measured change being recorded.

Written selection criteria keep that list consistent across clinicians. For patients already scheduled for joint replacement, the preoperative window is covered in what to have measured before surgery.

What Measura measures in this pathway

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It performs no injections, no imaging and no treatment; radiographs and joint imaging are done elsewhere, and findings return to the ordering physician. Three measurements apply:

• Laboratory panels for the glycemic and lipid picture, with fasting insulin reported beside glucose and A1c, plus inflammatory markers and lipid particle detail.
• Bioimpedance body composition to separate fat from lean mass, the only practical way to catch sarcopenic obesity before it is advanced.
• Vestibular and balance testing where an older patient with lower-limb osteoarthritis reports unsteadiness, documented with a cognitive baseline through the cognitive assessment and fall prevention workflow.

None of these measures cartilage, and no metabolic result diagnoses or grades osteoarthritis. What they supply is the phenotype the radiograph cannot show.

Building it into the referral

Attach the panel to the diagnosis rather than to the encounter. A standing order that triggers metabolic labs and body composition on a new hand osteoarthritis diagnosis, or on any osteoarthritis diagnosis under sixty, is the version that survives a busy clinic. Recorded at the annual wellness visit, where fall risk and cognition are already structured, the results support the cardiometabolic documentation those visits capture, as documentation rather than as an indication in itself. The same reasoning for tendon disease is in tendinopathy as a metabolic signal, and the pre-procedure version is in metabolic screening before repeat joint injections.

The limits, stated once: almost all of this is observational, most of the metabolic syndrome signal in weight-bearing joints is adiposity rather than the syndrome, and reverse causation is possible where pain limits activity. Trials that could settle causation enroll one disease at a time and screen out the patient with obesity, diabetes, depression and three painful joints, who is the patient actually in the exam room. The hand data and the genetic data keep the systemic reading alive, and the practice position follows from them. Measure the terrain in the patient whose joints cannot be explained by what they carry, then measure it again to see whether it moved.

Frequently asked questions

References

• Louati, K., Vidal, C., Berenbaum, F., & Sellam, J. (2015). Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open, 1(1), e000077. https://doi.org/10.1136/rmdopen-2015-000077
• Yusuf, E., Nelissen, R. G., Ioan-Facsinay, A., Stojanovic-Susulic, V., DeGroot, J., van Osch, G., Middeldorp, S., Huizinga, T. W., & Kloppenburg, M. (2010). Association between weight or body mass index and hand osteoarthritis: a systematic review. Annals of the Rheumatic Diseases, 69(4), 761-765. https://doi.org/10.1136/ard.2008.106930
• Sanchez-Santos, M. T., Judge, A., Gulati, M., Spector, T. D., Hart, D. J., Newton, J. L., Arden, N. K., & Kluzek, S. (2019). Association of metabolic syndrome with knee and hand osteoarthritis: A community-based study of women. Seminars in Arthritis and Rheumatism, 48(5), 791-798. https://doi.org/10.1016/j.semarthrit.2018.07.007
• Charton, A., Lacoste-Badie, R., Tuffet, S., Rousseau, A., Maheu, E., Fautrel, B., Dougados, M., Berenbaum, F., Courties, A., & Sellam, J. (2025). Metabolic syndrome is associated with more pain in hand osteoarthritis: Results from the DIGICOD cohort. Osteoarthritis and Cartilage Open, 7(1), 100573. https://doi.org/10.1016/j.ocarto.2025.100573
• Andrea, D., Karin, M., Johanna, V., Stefan, L. L., Martin, E., & Ali, K. (2026). The role of metabolic syndrome in osteoarthritis development: Is obesity the key driver? Osteoarthritis and Cartilage Open, 8(1), 100739. https://doi.org/10.1016/j.ocarto.2025.100739
• Wang, J., Peng, L., Xu, P., Guo, F., Xu, X., Wang, J., Yu, H., Xu, K., Yang, Z., Guo, J., & Yang, M. (2025). Unraveling the connection between obesity, metabolic syndrome and osteoarthritis risk: a large-observational study. Diabetology & Metabolic Syndrome, 18(1), 27. https://doi.org/10.1186/s13098-025-02059-y
• Huang, J. X., Xu, S. Z., Tian, T., Wang, J., Jiang, L. Q., He, T., Meng, S. Y., Ni, J., & Pan, H. F. (2025). Genetic Links Between Metabolic Syndrome and Osteoarthritis: Insights From Cross-Trait Analysis. The Journal of Clinical Endocrinology and Metabolism, 110(2), e461-e469. https://doi.org/10.1210/clinem/dgae169
• Ma, Z., Zhang, Y., Li, L., Zheng, G., Yang, H., Zhang, R., Li, Y., Wang, W., Ji, C., Xia, Y., & Zhao, Y. (2026). Association of cardiovascular-kidney-metabolic syndrome with risk of hip/knee osteoarthritis: A prospective cohort study. Maturitas, 212, 109056. https://doi.org/10.1016/j.maturitas.2026.109056
• Bliddal, H., Bays, H., Czernichow, S., Udden Hemmingsson, J., Hjelmesaeth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Velez Sanchez, P., Wharton, S., Wizert, A., & Kristensen, L. E. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine, 391(17), 1573-1583. https://doi.org/10.1056/NEJMoa2403664
• Wu, Q., Xu, Z., Ma, X., Li, J., Du, J., Ji, J., Ling, X., Kan, J., & Zhao, M. (2024). Association of low muscle mass index and sarcopenic obesity with knee osteoarthritis: a systematic review and meta-analysis. Journal of the International Society of Sports Nutrition, 21(1), 2352393. https://doi.org/10.1080/15502783.2024.2352393
• Zhang, Y., Li, X., Wang, Y., Ge, L., Pan, F., Winzenberg, T., & Cai, G. (2023). Association of knee and hip osteoarthritis with the risk of falls and fractures: a systematic review and meta-analysis. Arthritis Research & Therapy, 25(1), 184. https://doi.org/10.1186/s13075-023-03179-4

Related reading

• Tendinopathy as a Metabolic Signal: Screening Before the Procedure
• Corticosteroid-Induced Hyperglycemia After Joint Injections
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.